Renal osteodystrophy: Role of calcimimetics

American Journal of Kidney Diseases

Volumn 41, Issue 3 SUPPL. 1, 2003, Pages

  Hörl, Walter H ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Calcimimetics; Calcium; Parathyroid hormone (PTH); Phosphorus; Secondary hyperparathyroidism (HPT)

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D DERIVATIVE;

CALCIUM BLOOD LEVEL; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; HORMONE BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; LONG TERM CARE; MALABSORPTION; PARATHYROID HORMONE RELEASE; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0037374653     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2003.50096     Document Type: Conference Paper

References (19)

1. Locatelli F, Cannata-Andia JB, Drüeke TB, et al: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17:723-731, 2002
2. Pierratos A, Ouwendyk M, Francoeur R, et al: Nocturnal hemodialysis: Three-year experience. J Am Soc Nephrol 9:859-868, 1998
3. Schroeder NJ, Cunningham J: What's new in vitamin D for the nephrologist? Nephrol Dial Transplant 15:460-466, 2000
4. 2+-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
5. Nemeth EF, Bennett SA: Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant 13:1923-1925, 1998
6. Spurney RF, Pi M, Flannery P, Quarles LD: Aluminum is a weak agonist for the calcium-sensing receptor. Kidney Int 55:1750-1758, 1999
7. Schömig M, Ritz E: Management of disturbed calcium metabolism in uraemic patients: 3. Potential perspectives - Calcimimetics. Nephrol Dial Transplant 15:S30-S31, 2000 (suppl 5)
8. Goodman WG: Calcimimetic agents and secondary hyperparathyroidism: Treatment and prevention. Nephrol Dial Transplant 17:204-207, 2002
9. Silverberg SJ, Bone HG, Marriott TB, et al: Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337:1506-1510, 1997
10. Shoback DM, Firek AF, Mims RB, et al: The effect of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism (PHPT). J Bone Miner Res 16:S303, 2001 (suppl 1)
11. Peacock M, Shoback DM, Greth WE, et al: The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism (PHPT). J Bone Miner Res 16:S163, 2001 (suppl 1)
12. Wada M, Furuya Y, Sakiyama J, et al: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977-2983, 1997
13. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448-453, 1998
14. Antonsen JE, Sherrard DJ, Andress DL: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223-227, 1998
15. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436-445, 2000
16. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083-1088, 1998
17. Goodman WG, Hladik GA, Turner SA, et al: The calcimimetic agent AMG 073 lowers plasma hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024, 2002
18. Drüeke T, Cunningham J, Goodman WG, et al: Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073. J Am Soc Nephrol 12:764A, 2001 (abstr)
19. Lindberg JS, Moe SM, Goodman WG, et al: The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63:248-254, 2003